Inflammation in Cardiovascular Disease
In their review of systemic inflammation and arrhythmogenesis, Yalta and Yalta considered potential trigger mechanisms associated with inflammation, causation of arrhythmias, clinical implications, and possible role of anti-inflammatory medications in the management of arrhythmias. 1 With the extensive association of inflammation with multiple disease entities including cardiovascular (CV) ones, it is relevant to consider potential associations and possible management of atrial fibrillation (AF), especially since it is the most prevalent arrhythmia in clinical medicine. It is estimated that 3 million adults in the United States have been diagnosed with AF and the prevalence is estimated to rise to 12.1 million in 2030, due to the increasing numbers of the elderly in the US population. 2 Therefore, any disease with increased association with inflammation could be a trigger for increased CV risk including arrhythmias, especially highly prevalent AF.
Sources of Inflammation in CV disease
Multiple disease states have an association with inflammation, an example of which is giant cell arthritis (GCA), the diagnosis of which still involves temporal artery biopsy. 3 Glucocorticoids are standard treatment for GCA, but other antiinflammatory regimens may contribute to remission. 3 Psoriasis, psoriatic arthritis, and rheumatoid arthritis (RA) are all associated with inflammation which, in turn, is effected by pro-inflammatory cytokines. 4 In RA, flow-mediated dilatation of the brachial artery (when reduced) is an early measure of premature atherosclerosis and CV disease, is decreased. 5 In lupus erythematosus, premature coronary artery disease (CAD) is well established, with the most frequent related factors being antiphospholipid antibodies, increased high-sensitivity Creactive protein (hsCRP), and renal disease. 6 Infectious illnesses in their acute and subacute phase are associated with inflammation that interacts with the CV system. Pneumonia associated with chlamydia pneumoniae has been considered to play a major role in causing atherosclerotic CV disease due to enhancement of inflammation by bacteria. 7 Chagas disease, caused by Trypanosoma cruzi, a protozoon, has an inflammatory component with a chemokine associated with leukocyte migration to sites of inflammation. 8 There is evidence that other noninfectious chronic inflammatory diseases, such as inflammatory bowel disease (IBD), have a significant increase in risk of CV disease, 9 especially during active IBD. 10 Diabetes mellitus is a chronic disease where low-grade systemic inflammation and abnormal microvascular function are associated with insulin resistance, a major risk factor for CV disease. The metabolic syndrome (MetS) is associated with increased pro-inflammatory cytokines such as interleukin (IL) 6 and tissue necrosis factor a, whereas anti-inflammatory cytokines, such as IL-10, ghrelin, and adiponectin, are decreased. 12 Genetics may also play a role in chronic diseases associated with inflammation. 13 Environmental factors have a relationship with inflammation. Diet has major importance in avoiding inflammation. Unhealthy diet can be associated with inflammation, MetS, and increased CV risk.
14 An exemplary healthy diet is the Dietary Approaches to Stop Hypertension diet, which has been shown to decrease circulating plasma inflammatory markers. 15 Abnormal circadian rhythms and performance of physical activity, such as with sleep deprivation, may result in increased inflammation with increased CV risk. 16 Air pollution is associated with increased CV risk, prothrombotic effects, endothelial dysfunction, systemic inflammation, oxidative stress, and pulmonary inflammation. 17 There is much evidence for an association of periodontal disease with increased CV risk with atherosclerosis triggered by resultant systemic inflammation and endothelial dysfunction. 18 Systematic reviews suggest improved CV outcomes with treatment of periodontitis, due to decreased inflammation, but confirmation or refutation of this cannot be affirmed.
Apical periodontitis (bacteria-associated inflammation around tooth root apices) appears to have the highest association with CV disease.
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Prevention of Inflammation in CV disease
Because of the postulated association of CAD with Chlamydia pneumoniae, there has been an interest in the use of antibiotics to prevent CAD and other forms of atherosclerosis. However, a meta-analysis of antibiotic therapy in patients with CAD from 1966 to 2005 found no overall benefit of antibiotics for reduced CAD events or decreased CAD mortality. 22 Exercise is considered beneficial for the CV system. A meta-analysis found that exercise training decreases hsCRP, both in healthy adults and adults with cardiac disease. 23 Similar results of decreased hsCRP levels were found in another metaanalysis of exercise training. 24 Dietary flavonoids have been associated with decreased inflammation and decreased oxidative stress, although consistent effects have not been documented. 25 Marine-derived n-3 polyunsaturated fatty acids have been reported to decrease proinflammatory eicosanoid concentrations in RA and in individuals at high risk of CV disease. 26 Dietary olive oil has been associated with decreased levels of hsCRP and IL-6, suggesting decreased inflammation as a CV benefit of olive oil. 27 Dietary phenolics other than flavonoids have also been shown to have anti-inflammatory effects. 28 
Miscellaneous AF, Increased Inflammation, and Possible Management
There may be a significant role played by inflammation in the occurrence and continuation of AF, and inflammatory markers such as CRP (which is considered as a separate marker from hsCRP) and IL-6 are associated with AF, failure of cardioversion, and associated thrombogenesis. 29 A meta-analysis of patients with AF following catheter ablation reported on 7 available studies including 526 patients and found higher baseline CRP levels in the patients with more AF recurrence postablation. 30 A meta-analysis involving 7 prospective observational studies following electrical cardioversion that included 420 patients found increased CRP levels associated with recurrence of AF. 31 Another meta-analysis reported increased markers of inflammation such as IL-6 and CRP associated with increased AF in the general population, in patients who had had coronary artery bypass graft (CABG) surgery, who had had cardioversion, and who had had ablation. 32 There appears ample confirmation of the association of increased CRP and postoperative AF in CABG patients. 33 On the other hand, in a review of 63 studies, Jacob et al found that of inflammatory biomarkers, only increased white blood cells yielded reliable prediction of postoperative AF in CABG patients. 34 A meta-analysis of 11 studies involving septicemia reported new-onset AF frequently associated, which increased probability of a worse outcome. 35 Severe septicemia especially has an association with new-onset AF which in turn is associated with increased hospital stroke and mortality, as compared to patients with preexisting AF or without AF. 36 Association of CV problems with prolonged intensive training is unresolved. In an exploratory literature analysis based on more than 16 000 Medline-indexed articles, prolonged excessive exercise had an association with chronic inflammation, increased CRP was firmly associated with the occurrence of AF, and anti-inflammatory medications were associated with decreasing CRP and lessening AF. 37 However, the author commented on an absence of articles that correlated all 3 concepts.
There is an association between gastroesophageal reflux disease (GERD) and inflammation. 38 Epidemiologic data from 8 observational studies showed an increased risk of AF with GERD, especially for more severe GERD. 39 Treatment with proton pump inhibitors has been postulated to help in reversion to sinus rhythm, but obviously, currently nonexistent randomized clinical trials are essential.
Hyperuricemia is associated with AF including after cardiac surgery. The resultant intracellular uric acid concentration appears to be more important than serum or plasma uric acid and this brings into play uric acid transporters as possible therapeutic targets. 40 In a meta-analysis of 9 studies, it was found that serum uric acid has an association with AF in both crosssectional and cohort studies. 41 There is also a significant relationship of uric acid to inflammation and multiple inflammatory markers. 42 Colchicine, a potent anti-inflammatory agent, may have a promising role in the prevention of AF after cardiac surgery and pulmonary vein isolation procedures. 43 In a pooled analysis of patients following interventional or surgical cardiac procedures, it was found that of 286 patients on colchicine versus 298 patients on placebo, those on colchicine had an odds ratio of 0.44 (P < .001) of developing AF, compared with the placebo, indicating a possible prevention benefit. 44 There is an interest in the possible benefit of glucocorticoids in prevention of perioperative AF with cardiac surgery. In a pooled analysis of 42 randomized controlled trials including 7621 patients, it was found that glucocorticoid prophylaxis did not increase the all-cause infection rate and resulted in a decreased risk of perioperative AF, with a relative risk of 0.77 (P < .01). 45 Another meta-analysis involving 50 randomized controlled trials, which included 3323 adult cardiac surgery patients, found a relative risk of AF of 0.74 (P < .01), with glucocorticoids in a low dose (hydrocortisone in a total dose of 1000 mg) with no advantage for a higher dose. 46 Other metaanalyses have also supported glucocorticoids in prevention of AF after cardiac surgery. 47, 48 However, negative meta-analyses have also been published regarding any glucocorticoid benefit in preventing AF following cardiac surgery. 49 Use of statins in various situations to decrease AF risk is controversial in spite of inhibition of inflammation as a statin pleiotropic effect. 50 One meta-analysis reported that statins may decrease the risk of AF recurrence following cardioversion but not following ablation. 51 A major problem has been that studies reporting statin benefit in decreasing AF have been small observational ones. [52] [53] [54] In a literature search, Howard and Barnes found several observational studies with documented benefit of statins in decreasing perioperative AF in association with cardiac surgery but found only 1 randomized controlled trial with a significant decrease in AF after cardiac surgery. 55 Other meta-analyses conclude that statins may be beneficial in avoidance of AF following various surgeries but that there are insufficient data to support statin use solely for the prevention of AF. 56, 57 For the usual cardiac surgery patient undergoing CABG, the issue appears moot since such a patient with proven CAD should be on a statin unless there is a specific contraindication.
Inflammation has extensive association with several diseases including atherosclerosis, CV disease in general, and AF. The review of Yalta and Yalta considers possible triggers and mechanisms of arrhythmias with a possible relationship to inflammation.
1 Atrial fibrillation, the most prevalent arrhythmia, is a degenerative disease exacerbated by age, several diseases, metabolic abnormalities, and by some association with inflammation. The clinical issue with inflammation then becomes a therapeutic one regarding whether or not altering the inflammatory state by medications and/or other measures can decrease the occurrence of this very prevalent arrhythmia. The possible role of the circadian control of inflammation and its oscillations also should not be forgotten with, for example, the peak in white blood cells around midnight, 16 which could play a role in arrhythmogenesis, including AF. Antiinflammatory agents to target AF are definitely not ready for prime time but, especially after open heart surgery where AF is a major problem and when antiarrhythmics or b-blockers are ineffective, the judicious use of colchicine and corticosteroids may be of value. Statins, with their anti-inflammatory pleiotropic effect may also have benefit for prevention of AF following cardiac surgery, but this is very difficult to evaluate since CABG is the most prevalent cardiac surgical procedure and most such patients are already on a statin. Further consideration of medications to decrease inflammation and thereby AF is warranted when prolonged safe medication use is possible (certainly not the case with nonsteroidal anti-inflammatory drugs) and with further proof from randomized controlled trials.
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